Dimitrios Kouretas

Prof. Dr. Dimitrios Kouretas

Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2007 in Medicine & Science in Sports & Exercise
Verified
Journal Article
Closed access
Yiannis MichailidisYiannis Michailidis
Yiannis Michailidis
AJAthanasios Z. Jamurtas
Athanasios Z. Jamurtas
MNMichalis G. Nikolaidis
Michalis G. Nikolaidis
IFIoannis G. Fatouros
Ioannis G. Fatouros
YKYiannis Koutedakis
Yiannis Koutedakis
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Imental trial, the subjects exercised for 45 min at 70-75% V˙O2max and then at 90% V˙O2max to exhaustion on a treadmill; in the control trial, the subjects remained at rest. Blood samples were drawn before and after exercise (immediately after exercise and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 24 h). Reduced glutathione (GSH), oxidized glutathione (GSSG), GSH/GSSG, thiobarbituric acid-reactive substances (TBARS), protein carbonyls, catalase activity, and total antioxidant capacity (TAC) were determined. Results: The time to lowest concentration after exercise was 1.7 ± 0.7 h (mean ± SD) for GSH/GSSG, and the time to highest concentration after exercise was 1.2 ± 0.6 h for TBARS, 4.4 ± 0.5 h for protein carbonyls, 0.5 ± 0.4h for catalase, and 2.2 ± 0.9 h for TAC. The greatest change after exercise was −74 ± 9% for GSH/GSSG, 129 ± 29% for TBARS, 135 ± 53% for protein carbonyls, 51 ± 16% for catalase, and 24 ± 10% for TAC. Conclusion: There is no best time point applying to all markers for collecting blood samples after aerobic exercise. The optimum postexercise time points for blood collection in untrained individuals are immediately after exercise for catalase, 1 h for TBARS, 2 h for TAC, GSH, and GSSG, and 4 h after exercise for protein carbonyls....

25 February 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
EPEmiliano Panieri
Emiliano Panieri
Aleksandra Buha ĐorđevićAleksandra Buha Đorđević
Aleksandra Buha Đorđević
Pelin TELKOPARAN AKILLILARPelin TELKOPARAN AKILLILAR
Pelin TELKOPARAN AKILLILAR
DCDilek Cevik
Dilek Cevik
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Luciano SasoLuciano Saso
Luciano Saso
The nuclear factor erythroid 2-related factor 2 (NRF2)–Kelch-like ECH-associated protein 1 (KEAP1) regulatory pathway plays an essential role in protecting cells and tissues from oxidative, electrophilic, and xenobiotic stress. By controlling the transactivation of over 500 cytoprotective genes, the NRF2 transcription factor has been implicated in the physiopathology of several human diseases, including cancer. In this respect, accumulating evidence indicates that NRF2 can act as a double-edged sword, being able to mediate tumor suppressive or pro-oncogenic functions, depending on the specific biological context of its activation. Thus, a better understanding of the mechanisms that control NRF2 functions and the most appropriate context of its activation is a prerequisite for the development of effective therapeutic strategies based on NRF2 modulation. In line of principle, the controlled activation of NRF2 might reduce the risk of cancer initiation and development in normal cells by scavenging reactive-oxygen species (ROS) and by preventing genomic instability through decreased DNA damage. In contrast however, already transformed cells with constitutive or prolonged activation of NRF2 signaling might represent a major clinical hurdle and exhibit an aggressive phenotype characterized by therapy resistance and unfavorable prognosis, requiring the use of NRF2 inhibitors. In this review, we will focus on the dual roles of the NRF2-KEAP1 pathway in cancer promotion and inhibition, describing the mechanisms of its activation and potential therapeutic strategies based on the use of context-specific modulation of NRF2.

1 August 2018 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
NGNikolaos Georgiadis
Nikolaos Georgiadis
Konstantinos TsarouhasKonstantinos Tsarouhas
Konstantinos Tsarouhas
CTChristina Tsitsimpikou
Christina Tsitsimpikou
AVAlexandros Vardavas
Alexandros Vardavas
RRRamin Rezaee
Ramin Rezaee
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas

1 November 2014 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
CMChrysoula M. Matthaiou
Chrysoula M. Matthaiou
NGNikolaos Goutzourelas
Nikolaos Goutzourelas
DSDimitrios Stagos
Dimitrios Stagos
ESEleni Sarafoglou
Eleni Sarafoglou
AJAthanasios Jamurtas
Athanasios Jamurtas
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas

1 January 2021 in Toxicology Reports
Verified
Journal Article
Open access
Konstantinos FarsalinosKonstantinos Farsalinos
Konstantinos Farsalinos
Konstantinos PoulasKonstantinos Poulas
Konstantinos Poulas
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas
Apostolos VantarakisApostolos Vantarakis
Apostolos Vantarakis
MLMichalis Leotsinidis
Michalis Leotsinidis
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
• The COVID-19 pandemic has challenged the healthcare capacity of many countries. • Strict, horizontal lockdowns have adverse social, economic and health effects that have not been fully considered. • Primary and community care have multiple roles in COVID-19 pandemic mitigation. • Greece is a case example of a country which neglected primary and community care, and in November 2020 implemented a second horizontal lockdown. • Primary and community care, represents the only realistic strategy for successful COVID-19 pandemic mitigation in the long-term.

1 July 2014 in Food Chemistry
Verified
Journal Article
Closed access
EKEfthalia Kerasioti
Efthalia Kerasioti
DIMITRIOS STAGOSDIMITRIOS STAGOS
DIMITRIOS STAGOS
APAlexandros Priftis
Alexandros Priftis
SAStefanos Aivazidis
Stefanos Aivazidis
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
Dimitrios KouretasDimitrios Kouretas
Dimitrios Kouretas